Cytokinetics, Inc. (CYTK), Friday announced that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for MYQORZO, also known as aficamten, in the European Union for the patients with symptomatic obstructive hypertrophic cardiomyopathy.
The positive opinion is based on the clinical evidence from SEQUOIA-HCM, which demonstrated the safety and efficacy of MYQORZO in the participants.
The company expects the final decision from the European Commission in the first quarter of 2026.
Meanwhile, the Food & Drug Administration is reviewing a New Drug Application for aficamten with a Prescription Drug User Fee Act target action date of December 26, 2025.
Currently, CYTK is trading at $61.97, up 1.98 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.